Research explained · Reviewed September 15, 2026
Metabolic peptide research has made striking progress. Semaglutide, tirzepatide and retatrutide show how studying different receptor combinations can expand our understanding of weight regulation.
How their receptor targets differ
| Peptide | Receptor activity | Question to ask |
|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Which population and formulation were studied? |
| Tirzepatide | GIP and GLP-1 receptor agonist | Was the comparison direct and randomized? |
| Retatrutide | GIP, GLP-1 and glucagon receptor agonist | Are results fully published or only topline? |
A receptor is a molecular target through which a compound can trigger a biological response. Describing one, two or three targets explains part of the mechanism; it does not capture the full balance of effectiveness, tolerability and uncertainty. The target profiles are described in the tirzepatide–semaglutide comparison and the retatrutide phase 2 trial.
What a direct comparison tells us
A 2025 randomized, open-label trial enrolled 751 adults with obesity without diabetes. At 72 weeks, the estimated mean body-weight change was −20.2% with tirzepatide and −13.7% with semaglutide. Both groups followed the trial’s maximum-tolerated-dose approach. This is evidence from a comparison conducted within one study, with a defined population and follow-up period. It is not a promise of an individual result. Read the head-to-head trial.
Open-label means participants and investigators knew the assigned treatment. Randomization remains valuable, but study design, discontinuation and the method used to handle missing results still matter when interpreting the headline.
Where retatrutide fits
In the 2023 phase 2 study, 338 adults were randomized to retatrutide or placebo. The highest studied retatrutide group had a mean weight reduction of 24.2% at 48 weeks. That result came from a different trial, with different participants, duration and treatment groups. Placing 24.2%, 20.2% and 13.7% in a simple league table would hide those differences. Read the phase 2 study.
A July 23, 2026 sponsor update reported positive topline findings from two additional phase 3 trials. The announcement describes retatrutide as investigational. Topline announcements provide an early summary; they should be labelled separately from a full peer-reviewed publication. Read the dated phase 3 announcement. A separate retatrutide-versus-tirzepatide trial listing also illustrates why a study’s existence must not be confused with published comparative outcomes.
How to read the next headline
- Check whether the study included diabetes, obesity or another defined condition.
- Compare the follow-up period and outcome definition before comparing percentages.
- Read adverse events and treatment discontinuation alongside average weight change.
- Distinguish a published paper from a conference summary or sponsor announcement.
There is no valid dose conversion based simply on the number of receptor targets. Results obtained with a clinical-trial formulation also do not establish the identity, performance or safety of an unrelated research vial. For the site’s available compound references, use the peptide library.